seribantumab
elevation oncology
['crest', 'seribantumab']
#asco22 crestone is a phase ii study with registration potential of seribantumab 3g iv weekly in pts with #nrg1 fusion positive cancers. cohort 1 (n=55) includes pts with no prior erbb-directed therapy and the focus of this presentation. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him